Financial Gravity Wealth Inc. purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 839 shares of the company’s stock, valued at approximately $81,000.
Several other institutional investors and hedge funds have also modified their holdings of LIVN. Financial Gravity Companies Inc. acquired a new position in shares of LivaNova during the fourth quarter valued at $60,000. South Dakota Investment Council acquired a new position in shares of LivaNova during the fourth quarter valued at $110,000. Ffcm LLC acquired a new position in shares of LivaNova during the fourth quarter valued at $133,000. grace capital increased its holdings in shares of LivaNova by 80.0% during the fourth quarter. grace capital now owns 1,800 shares of the company’s stock valued at $143,000 after purchasing an additional 800 shares during the period. Finally, Meeder Asset Management Inc. increased its holdings in shares of LivaNova by 130.8% during the fourth quarter. Meeder Asset Management Inc. now owns 1,632 shares of the company’s stock valued at $148,000 after purchasing an additional 925 shares during the period. 89.62% of the stock is currently owned by institutional investors.
A number of brokerages have recently commented on LIVN. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. UBS Group raised their price target on LivaNova from $100.00 to $105.00 and gave the company a “neutral” rating in a report on Tuesday, April 2nd. BTIG Research reissued a “hold” rating on shares of LivaNova in a report on Tuesday, March 5th. Zacks Investment Research raised LivaNova from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $120.00 price target (down from $135.00) on shares of LivaNova in a report on Wednesday, February 27th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $113.75.
NASDAQ:LIVN opened at $66.99 on Monday. The stock has a market cap of $3.23 billion, a P/E ratio of 21.13, a PEG ratio of 2.39 and a beta of 0.87. LivaNova PLC has a 52-week low of $65.66 and a 52-week high of $131.54. The company has a current ratio of 1.07, a quick ratio of 0.76 and a debt-to-equity ratio of 0.09.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 27th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.05. The firm had revenue of $297.00 million for the quarter, compared to analyst estimates of $294.98 million. LivaNova had a positive return on equity of 9.64% and a negative net margin of 17.11%. LivaNova’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. Sell-side analysts anticipate that LivaNova PLC will post 2.96 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/22/financial-gravity-wealth-inc-invests-81000-in-livanova-plc-livn.html.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Read More: Why is total return important?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.